Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved encorafenib in combination with binimetinib for reimbursement as a treatment option for the treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.
This is written in the approval document as:
Treatment of adult patients with advanced (unresectable or metastatic) melanoma with a BRAF V600 mutation.
Citation
Encorafenib and Binimetinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | BRAF p.V600E | Melanoma | Binimetinib, Encorafenib | |
| Sensitivity (+) | BRAF p.V600K | Melanoma | Binimetinib, Encorafenib |